Objective: The aim of this study was to evaluate the effectiveness and tolerability of biological treatments administered after an initial treatment with Rituximab. Methods: A cross-sectional study was conducted using the baseline data of the Moroccan biotherapy registry for RBSMR. Demographics and disease features were compared using descriptive statistics. The study evaluated the effectiveness of switching to a new biological by measuring DAS28 and ΔDAS28 at baseline, 6 months, and 12 months of follow-up. Adverse effects were also assessed. The study compared the switcher and non-switcher groups, with a significance level set at p < 0.05. Results: A total of 165 patients diagnosed with rheumatoid arthritis were treated with Rituximab as their first biologic. The mean age of patients was 51.79 ± 11.27 years with a majority of females (87.9%). The mean duration of the disease was 13.84 ± 9.07 years. In 21.81% of cases, 36 patients required at least one switch due to ineffectiveness. After 1 year of follow-up, switchers had a greater ΔDAS 28-ESR (-0.31 ± 2.22) compared to non-switchers (-0.17 ± 1.72). At 1-year follow-up, 53.6% of switchers were in remission/LDA compared to 43.8% of non-switchers. Adverse effects to biotherapy were more common in switchers (44.4%) than non-switchers (31%), with infections being the most common adverse effect in both groups (22.2% and 13.2%, respectively). Conclusion: Switching after Rituximab in RA patients may be as effective and tolerable as switching after TNF inhibitors.